Jump to content

N1-Methylpseudouridine

From Wikipedia, the free encyclopedia
(Redirected from N1-methylpseudouridine)
N1-Methylpseudouridine
Names
IUPAC name
5-[(2S,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpyrimidine-2,4-dione
Other names
1-Methylpseudouridine; m1Ψ
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
UNII
  • InChI=1S/C10H14N2O6/c1-12-2-4(9(16)11-10(12)17)8-7(15)6(14)5(3-13)18-8/h2,5-8,13-15H,3H2,1H3,(H,11,16,17)/t5-,6-,7-,8+/m1/s1
    Key: UVBYMVOUBXYSFV-XUTVFYLZSA-N
  • O[C@H]1[C@@](O[C@H](CO)[C@H]1O)(C=2C(=O)NC(=O)N(C)C2)[H]
Properties
C10H14N2O6
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

N1-Methylpseudouridine (abbreviated m1Ψ) is a natural archaeal tRNA component,[1] and "hypermodified" pyrimidine nucleoside used in biochemistry and molecular biology for in vitro transcription and is found in the SARS-CoV-2 mRNA vaccines tozinameran (Pfizer–BioNTech) and elasomeran (Moderna).[2]

Properties

[edit]

N1-Methylpseudouridine is the methylated derivative of pseudouridine. It is used in in vitro transcription and for the production of RNA vaccines.[3][4] In vertebrates, it stimulates significantly less activation of the innate immune response compared to uridine,[5] while the translation is stronger.[6][7] In protein biosynthesis, it is read like uridine and enables comparatively high protein yields.[7][8] The nucleoside itself can be made by chemical methylation of pseudouridine.[9]

While pseudouridine can wobble-pair with bases other than A,[10] work examining COVID-19 modRNA vaccines that replace all their uridines with N1-methylpseudouridine show faithful protein production.[11]

More recent work from Mulroney and colleagues has identified that N1-methylpseudouridine can give rise to slippery sequences that promote ribosomal frameshifting.[12] This issue is readily correctable through the replacement of slippery sequences with synonymous codons. The frameshifting is not known to contribute to any safety issues with regard to current mRNA vaccines, nor has it been shown to limit their effectiveness. In work from Mulroney and colleagues, mice immunized with the Bnt162b2 vaccine (Pfizer–BioNTech) demonstrate a greater T cell response against in-frame spike protein than those receiving Vaxzevria (Oxford–AstraZeneca), despite the latter not demonstrating meaningful production of frameshifted sequences. In human donors, the degree of recognition of frameshifted peptides by T cells varies greatly, suggesting that the extent to which frameshifting occurs may vary greatly as well. Importantly, frameshifted products are rare but well-defined events in protein production, including in viral infections, and can give rise to sequences that can be targeted by the immune system.[13][14] Furthermore, despite significant disparity at the level of nucleotide sequences between COVID-19 vaccines from Pfizer/BioNTech and Moderna,[15] the safety profile of both vaccines is comparable,[16] arguing against any meaningful effect of frameshifting on the safety profile of the vaccines.

History

[edit]

In 2016, a protocol for large-scale synthesis of the nucleoside triphosphate from the ribonucleoside was published.[17]

In 2017–2018 it was tested in vaccines against Zika,[18][19][20] HIV-1,[20] influenza,[20] and Ebola.[21][2]: 5 

References

[edit]
  1. ^ Wurm JP, Griese M, Bahr U, Held M, Heckel A, Karas M, et al. (March 2012). "Identification of the enzyme responsible for N1-methylation of pseudouridine 54 in archaeal tRNAs". RNA. 18 (3): 412–420. doi:10.1261/rna.028498.111. PMC 3285930. PMID 22274954. In contrast, in most archaea this position is occupied by another hypermodified nucleotide: the isosteric N1-methylated pseudouridine
  2. ^ a b Morais P, Adachi H, Yu YT (2021-11-04). "The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines". Frontiers in Cell and Developmental Biology. 9: 789427. doi:10.3389/fcell.2021.789427. PMC 8600071. PMID 34805188.
  3. ^ Knudson CJ, Alves-Peixoto P, Muramatsu H, Stotesbury C, Tang L, Lin PJ, et al. (September 2021). "Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection". Molecular Therapy. 29 (9): 2769–2781. doi:10.1016/j.ymthe.2021.05.011. PMC 8417516. PMID 33992803.
  4. ^ Krienke C, Kolb L, Diken E, Streuber M, Kirchhoff S, Bukur T, et al. (January 2021). "A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis". Science. 371 (6525): 145–153. Bibcode:2021Sci...371..145K. doi:10.1126/science.aay3638. PMID 33414215. S2CID 231138578.
  5. ^ Nelson J, Sorensen EW, Mintri S, Rabideau AE, Zheng W, Besin G, et al. (June 2020). "Impact of mRNA chemistry and manufacturing process on innate immune activation". Science Advances. 6 (26): eaaz6893. Bibcode:2020SciA....6.6893N. doi:10.1126/sciadv.aaz6893. PMC 7314518. PMID 32637598.
  6. ^ Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T (November 2015). "N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice". Journal of Controlled Release. 217: 337–344. doi:10.1016/j.jconrel.2015.08.051. hdl:1854/LU-6993270. PMID 26342664.
  7. ^ a b Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N (June 2017). "N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density". Nucleic Acids Research. 45 (10): 6023–6036. doi:10.1093/nar/gkx135. PMC 5449617. PMID 28334758.
  8. ^ Parr CJ, Wada S, Kotake K, Kameda S, Matsuura S, Sakashita S, et al. (April 2020). "N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells". Nucleic Acids Research. 48 (6): e35. doi:10.1093/nar/gkaa070. PMC 7102939. PMID 32090264.
  9. ^ Earl RA, Townsend LB (June 1977). "A chemical synthesis of the nucleoside 1-methylpseudouridine". Journal of Heterocyclic Chemistry. 14 (4): 699–700. doi:10.1002/jhet.5570140437.
  10. ^ Kierzek E, Malgowska M, Lisowiec J, Turner DH, Gdaniec Z, Kierzek R (March 2014). "The contribution of pseudouridine to stabilities and structure of RNAs". Nucleic Acids Research. 42 (5): 3492–3501. doi:10.1093/nar/gkt1330. PMC 3950712. PMID 24369424.
  11. ^ Kim, Kyusik Q.; Burgute, Bhagyashri D.; Tzeng, Shin-Cheng; Jing, Crystal; Jungers, Courtney; Zhang, Junya; Yan, Liewei L.; Vierstra, Richard D.; Djuranovic, Sergej; Evans, Bradley S.; Zaher, Hani S. (2022-08-30). "N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products". Cell Reports. 40 (9): 111300. doi:10.1016/j.celrep.2022.111300. ISSN 2211-1247. PMC 9376333. PMID 35988540.
  12. ^ Mulroney, Thomas E.; Pöyry, Tuija; Yam-Puc, Juan Carlos; Rust, Maria; Harvey, Robert F.; Kalmar, Lajos; Horner, Emily; Booth, Lucy; Ferreira, Alexander P.; Stoneley, Mark; Sawarkar, Ritwick; Mentzer, Alexander J.; Lilley, Kathryn S.; Smales, C. Mark; von der Haar, Tobias (2023-12-06). "N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting". Nature. 625 (7993): 189–194. doi:10.1038/s41586-023-06800-3. ISSN 1476-4687. PMC 10764286. PMID 38057663.
  13. ^ Hogan, Michael J.; Maheshwari, Nikita; Begg, Bridget E.; Nicastri, Annalisa; Hedgepeth, Emma J.; Muramatsu, Hiromi; Pardi, Norbert; Miller, Michael A.; Reilly, Shanelle P.; Brossay, Laurent; Lynch, Kristen W.; Ternette, Nicola; Eisenlohr, Laurence C. (November 2023). "Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response". Nature Immunology. 24 (11): 1933–1946. doi:10.1038/s41590-023-01644-5. ISSN 1529-2916. PMID 37828378. S2CID 260829874.
  14. ^ Dolan, Brian P.; Li, Lily; Takeda, Kazuyo; Bennink, Jack R.; Yewdell, Jonathan W. (2010-02-01). "Defective Ribosomal Products Are the Major Source of Antigenic Peptides Endogenously Generated from Influenza A Virus Neuraminidase". Journal of Immunology. 184 (3): 1419–1424. doi:10.4049/jimmunol.0901907. ISSN 0022-1767. PMC 2940057. PMID 20038640.
  15. ^ Zhang, Lizhou; More, Kunal R.; Ojha, Amrita; Jackson, Cody B.; Quinlan, Brian D.; Li, Hao; He, Wenhui; Farzan, Michael; Pardi, Norbert; Choe, Hyeryun (2023-10-11). "Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability". npj Vaccines. 8 (1): 156. doi:10.1038/s41541-023-00751-6. ISSN 2059-0105. PMC 10567765. PMID 37821446.
  16. ^ Dickerman, Barbra A.; Madenci, Arin L.; Gerlovin, Hanna; Kurgansky, Katherine E.; Wise, Jessica K.; Figueroa Muñiz, Michael J.; Ferolito, Brian R.; Gagnon, David R.; Gaziano, J. Michael; Cho, Kelly; Casas, Juan P.; Hernán, Miguel A. (2022-07-01). "Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans". JAMA Internal Medicine. 182 (7): 739–746. doi:10.1001/jamainternmed.2022.2109. ISSN 2168-6106. PMC 9194743. PMID 35696161.
  17. ^ Shanmugasundaram M, Senthilvelan A, Kore AR (December 2016). "Gram-Scale Chemical Synthesis of Base-Modified Ribonucleoside-5'-O-Triphosphates". Current Protocols in Nucleic Acid Chemistry. 67: 13.15.1–13.15.10. doi:10.1002/cpnc.20. PMID 27911496. S2CID 5143935.
  18. ^ Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. (March 2017). "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination". Nature. 543 (7644): 248–251. Bibcode:2017Natur.543..248P. doi:10.1038/nature21428. PMC 5344708. PMID 28151488. we designed a potent anti-ZIKV vaccine … containing the modified nucleoside 1-methylpseudouridine (m1Ψ)
  19. ^ Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. (March 2017). "Modified mRNA Vaccines Protect against Zika Virus Infection". Cell. 168 (6): 1114–1125.e10. doi:10.1016/j.cell.2017.02.017. PMC 5388441. PMID 28222903. The mRNA was synthesized … where the UTP was substituted with 1-methylpseudoUTP
  20. ^ a b c Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, et al. (June 2018). "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses". The Journal of Experimental Medicine. 215 (6): 1571–1588. doi:10.1084/jem.20171450. PMC 5987916. PMID 29739835. In this study, we characterize the immunogenicity of three vaccines consisting of m1Ψ-modified, FPLC-purified mRNA-LNPs encoding HIV-1 envelope (Env), ZIKV prM-E, and influenza virus hemagglutinin (HA)
  21. ^ Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A (January 2018). "Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease". The Journal of Infectious Diseases. 217 (3): 451–455. doi:10.1093/infdis/jix592. PMC 5853918. PMID 29281112. Two mRNA vaccines were synthesized … where the UTP were substituted with 1-methylpseudo UTP
Retrieved from "https://en.wikipedia.org/w/index.php?title=N1-Methylpseudouridine&oldid=1249816568"